Named on 4 rounds in the feed, most often at Series D+ and in Healthtech.
Rounds from 2025-09-25 to 2026-09-02
ROUNDS
4
led 1, joined 3
LED ROUNDS · USD
$33.3M
across 1 round · 1 co-led, split evenly
CO-INVESTORS
25
named beside it
Named on 4 rounds in the feed, most often at Series D+ and in Healthtech.
Rounds from 2025-09-25 to 2026-09-02
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Thyme Care Thyme Care enhances the cancer journey with expert oncology navigation and an oncology care team, partnering to improve access, outcomes, and costs. | Series E Verified against 4 of 8 sources | $125M | 2026-09-02 | [ PART ] |
Ollin Biosciences Ollin sells innovative therapies targeting serious eye diseases for patients. | Series B Verified against 4 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $330M | 2026-06-24 | [ PART ] |
Stipple Bio Stipple Bio develops targeted oncology therapies through precision mapping of tumor-specific epitopes for cancer treatment. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-06 | [ LEAD ] |
Thyme Care Thyme Care enhances the cancer journey with expert oncology navigation and an oncology care team, partnering to improve access, outcomes, and costs. | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $97M | 2025-09-25 | [ PART ] |